HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zakhartchouk, A. N. Articles by Babiuk, L. A. Search for Related Content PubMed PubMed Citation Articles by Zakhartchouk, A. N. Articles by Babiuk, L. A. Agricola Articles by Zakhartchouk, A. N. Articles by Babiuk, L. A.

Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice

¹ Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK, Canada S7N 5E3
² Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada L8N 3Z5
³ St Joseph's Hospital, Hamilton, ON, Canada L8N 4A6

Correspondence
Alexander N. Zakhartchouk
zakhartchouk{at}sask.usask.ca

Severe acute respiratory syndrome coronavirus (SARS-CoV) has been identified as the aetiological agent of SARS. Thus, vaccination against SARS-CoV may represent an effective approach towards controlling SARS. The nucleocapsid (N) protein is thought to play a role in induction of cell-mediated immunity to SARS-CoV and thus it is important to characterize this protein. In the present study, an E1/partially E3-deleted, replication-defective human adenovirus 5 (Ad5) vector (Ad5-N-V) expressing the SARS-CoV N protein was constructed. The N protein, expressed in vitro by Ad5-N-V, was of the expected molecular mass of 50 kDa and was phosphorylated. Vaccination of C57BL/6 mice with Ad5-N-V generated potent SARS-CoV-specific humoral and T cell-mediated immune responses. These results show that Ad5-N-V may potentially be used as a SARS-CoV vaccine.

This article has been cited by other articles:

				L. Gillim-Ross and K. Subbarao Emerging Respiratory Viruses: Challenges and Vaccine Strategies Clin. Microbiol. Rev., October 1, 2006; 19(4): 614 - 636. [Abstract] [Full Text] [PDF]

				D. T. M. Leung, W. W. C. van Maren, F. K. L. Chan, W. S. Chan, A. W. I. Lo, C. H. Ma, F. C. H. Tam, K. F. To, P. K. S. Chan, J. J. Y. Sung, et al. Extremely Low Exposure of a Community to Severe Acute Respiratory Syndrome Coronavirus: False Seropositivity due to Use of Bacterially Derived Antigens. J. Virol., September 1, 2006; 80(18): 8920 - 8928. [Abstract] [Full Text] [PDF]

				R. H. See, A. N. Zakhartchouk, M. Petric, D. J. Lawrence, C. P. Y. Mok, R. J. Hogan, T. Rowe, L. A. Zitzow, K. P. Karunakaran, M. M. Hitt, et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J. Gen. Virol., March 1, 2006; 87(Pt 3): 641 - 650. [Abstract] [Full Text] [PDF]

				S. R. Weiss and S. Navas-Martin Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus Microbiol. Mol. Biol. Rev., December 1, 2005; 69(4): 635 - 664. [Abstract] [Full Text] [PDF]